ArticleDiscover oncology2026
PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe malignant behavior of glioma is tightly associated with underlying complex molecular mechanisms. Poly(ADP-ribose) polymerase 4 (PARP4) has been implicated in several tumor types. Nevertheless, comprehensive studies addressing the role of PARP4 in glioma remain lacking.
methodsUtilizing publicly available datasets including the Chinese Glioma Genome Atlas (CGGA), Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), Connectivity Map (cMap) and other bioinformatics tools, we systematically assessed PARP4 expression, its clinical relevance, prognostic significance, associated biological processes, immune infiltration, and potential inhibitors in glioma. In addition, we performed functional assays to validate its oncogenic role in glioblastoma (GBM) cells.
resultsOur findings revealed that PARP4 expression was elevated in gliomas compared to normal brain tissue, and that higher PARP4 levels correlated with increased tumor grade and worse patient prognosis. The immune-analysis suggested that immunotherapies targeting immune checkpoint genes may be beneficial for glioma patients with elevated PARP4 expression. Endogenous PARP4 knockdown impaired GBM cell proliferation, S/G₂ cell-cycle progression and migratory/invasive behavior. Finally, through molecular docking we identified five small-molecule compounds as potential PARP4 inhibitors.
conclusionsTaken together, our study demonstrated PARP4 acts as an important tumor-promoting factor by favoring glioblastoma (GBM) cell proliferation and migration/invasion. Our findings suggested that PARP4 might serve as a novel independent prognostic biomarker and a promising therapeutic target for glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.